Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intoleranc...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-10-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/dasatinib-for-the-treatment-of-chronic-myeloid-leukemia-patient-select-peer-reviewed-article-DDDT |